Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) CFO Sean F. Moran bought 3,100 shares of the business’s stock in a transaction on Wednesday, March 14th. The shares were acquired at an average price of $6.60 per share, with a total value of $20,460.00. Following the completion of the purchase, the chief financial officer now directly owns 344,010 shares of the company’s stock, valued at $2,270,466. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ CRBP) remained flat at $$6.75 on Wednesday. 550,304 shares of the company’s stock traded hands, compared to its average volume of 998,547. Corbus Pharmaceuticals Holdings Inc has a 52-week low of $5.30 and a 52-week high of $10.50. The company has a market capitalization of $391.37, a P/E ratio of -10.23 and a beta of 2.09.
Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04). Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 85.97%. research analysts forecast that Corbus Pharmaceuticals Holdings Inc will post -0.73 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new position in shares of Corbus Pharmaceuticals in the 4th quarter valued at $164,000. Goldman Sachs Group Inc. bought a new position in Corbus Pharmaceuticals during the 4th quarter worth $219,000. Deutsche Bank AG raised its position in Corbus Pharmaceuticals by 53.0% during the 4th quarter. Deutsche Bank AG now owns 114,842 shares of the biopharmaceutical company’s stock worth $814,000 after purchasing an additional 39,770 shares during the last quarter. Geode Capital Management LLC raised its position in Corbus Pharmaceuticals by 10.2% during the 4th quarter. Geode Capital Management LLC now owns 409,365 shares of the biopharmaceutical company’s stock worth $2,905,000 after purchasing an additional 37,994 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new position in Corbus Pharmaceuticals during the 4th quarter worth $2,663,000. Institutional investors own 38.03% of the company’s stock.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.